These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9264506)

  • 1. Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.
    Cook JJ; Glass JD; Sitko GR; Holahan MA; Stupienski RF; Wallace AA; Stump GL; Hand EL; Askew BC; Hartman GD; Gould RJ; Lynch JJ
    Circulation; 1997 Aug; 96(3):949-58. PubMed ID: 9264506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
    Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
    Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
    Lynch JJ; Cook JJ; Sitko GR; Holahan MA; Ramjit DR; Mellott MJ; Stranieri MT; Stabilito II; Zhang G; Lynch RJ
    J Pharmacol Exp Ther; 1995 Jan; 272(1):20-32. PubMed ID: 7815334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
    Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.
    Hennan JK; Hong TT; Willens DE; Driscoll EM; Giboulot TA; Lucchesi BR
    Br J Pharmacol; 2002 Jul; 136(6):927-37. PubMed ID: 12110617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
    Rübsamen K; Hornberger W; Kirchengast M
    Thromb Haemost; 1995 Nov; 74(5):1353-60. PubMed ID: 8607122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo.
    Murphy NP; Pratico D; Fitzgerald DJ
    J Pharmacol Exp Ther; 1998 Aug; 286(2):945-51. PubMed ID: 9694954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.
    Egbertson MS; Cook JJ; Bednar B; Prugh JD; Bednar RA; Gaul SL; Gould RJ; Hartman GD; Homnick CF; Holahan MA; Libby LA; Lynch JJ; Lynch RJ; Sitko GR; Stranieri MT; Vassallo LM
    J Med Chem; 1999 Jul; 42(13):2409-21. PubMed ID: 10395482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
    Hoffmann P; Bernat A; Savi P; Herbert JM
    J Pharmacol Exp Ther; 1998 Aug; 286(2):670-5. PubMed ID: 9694919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
    Hong TT; Driscoll EM; White AJ; Sherigill A; Giboulot TA; Lucchesi BR
    J Pharmacol Exp Ther; 2003 Aug; 306(2):616-23. PubMed ID: 12734394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS; Bruttger O; Pally C; Hagenbach A
    Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
    Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T
    Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery.
    Kawano KI; Fujishima K; Ikeda Y; Kondo K; Umemura K
    J Cereb Blood Flow Metab; 2000 Jun; 20(6):988-97. PubMed ID: 10894182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
    Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):194-202. PubMed ID: 7511747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
    J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
    Gurbel PA; Cummings CC; Bell CR; Alford AB; Meister AF; Serebruany VL;
    Am Heart J; 2003 Feb; 145(2):239-47. PubMed ID: 12595840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.